|
Bilcare Receives US Patent For 3 Products
Bilcare Ltd. has obtained a patent in the USA for its pharmaceutical grade
metalised thermo-formable composite films.
This innovative packaging material will address multiple
concerns and limitations of the pharmaceutical products in the markets like
anti-counterfeit and anti-pass off. The unique products under this range are
Patina, Ultra and UtraTX. In March 2004, the company had filed patent
application for these three products in the US.
The pharma packaging industry in India depends on holograms
as a solution to prevent counterfeit. But holograms do not serve as identify for
genuineness, as it can also be duplicate. Another issue that proves serious to
patient is when they accidently consume the wrong drugs, as they are unable to
differentiate between the various drugs available. With the pharmaceutical grade
metalised films, Bilcare has developed products that will have their own unique
identity, either through colour or the overall finish to the product and can
address both these issue, strongly.
"Our vision to partner the global companies has been
strengthened with the new patient. We have won for the metalised films. Through
our innovative product range we are confident to revolutionize the pharma
packaging industry not only in India, but worldwide", said Mohan Bhandari,
chairman and managing director, Bilcare Ltd. This is perhaps just the
beginning and in times to come, Bilcare hopes to offer innovative solutions
through its strong emphasis on research, which address the needs of the life
science sector, he further added.
Dr. Praful Naik, global scientist officer, said, "In a world
where protection of intellectual property rights (IPR) is becoming a big
concern, especially in the pharmaceutical sector, where companies need to
protect their drug discoveries from counterfeit and pass offs, packaging is
going to play a very critical role. A patent for packaging material as unique is
as pharmaceutical grade metalised films will provide confidence to the industry
in terms of safer drug delivery. Bilcare has 7-8 product in their product
pipeline for worldwide patent. The company spends around 5 per cent net profit
on R&D, he said.
(Ref : Chronicle Pharmabiz dated December 7, 2006)
White Paper On Pharma Vision 2020 To Be Presented To Centre
Before March '07
India needs to be prepared with a sound and solid regulatory
enforcements to compete in the global market. The country is being recognized as
hub for clinical research and contract research. The pharma sector must gear up
for high technology process analytical systems to compete with the international
majors. Pharmaceutical Congress Association will present a White Paper on the
road map of the sector to the government before March 2007.
The paper broadly outlines the objectives of the charter
Pharma Vision 2020, devised by the Indian Pharmaceutical Congress Association
with the pharma industry and pharmacy professionals.
"We are looking at what India needs and how the government
should gear up for this, stated Drugs Controller General of India M
Venkateswarlu at a press conclave during the 58th IPC held at Mumbai.
Pharma Vision 2020 is creating a regulatory framework, which
is transparent and easy to follow. As India makes advances in science and
technology, there is a need to move away from the archaic systems, stated the
DCGI.
The road map envisages the role for realizing the Vision
2020. The industry needs to take advantage of the recent advances in
biotechnology and information technology to keep ahead.
Over the next 5 years, India will mature even further in drug
discovery, clinical trials and process formulation. It is now emerging as a
major player for conducting clinical research from phase I to phase IV. It is
also recognized as major manufacturer of generics in the US and European
markets. In such a scenario, efforts are on to address the regulatory issues in
drug development and clinical research. There is a need to implement the
Mashelkar Committee recommendations and constitute the Central Drug Authority at
the earliest, stated Subodh Priolkar, president IPA.
(Ref : Chronicle Pharmabiz dated December 7, 2006)
|
